Home › NCT06569082
CD34+ Selected Stem Cell for Poor Graft Function or Graft Failure
Recruiting
CD34+ Selected Donor Cell Boost for Management of Poor Graft Function or Primary or Secondary Graft Failure Following Allogeneic Hematopoietic Stem Cell Transplantation
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Recipient of allogeneic transplantation, adult ≥18 years, from any type of donor including matched related, matched unrelated, mismatched related or mismatched unrelated or haploidentical donor transplant. * Documented evidence of graft dysfunction or failure (a-c): 1. Primary graft Failure: Graft failure is defined as failure to achieve neutrophil engraftment by day +28 or lack of donor chimerism \> 50% by day 45 not due to the underlying malignancy; 2. Poor graft function is defined by at least 2 of the following 3 criteria: Hemoglobin \< 8 g/dL, ANC \< 0.5x109/L, and platelets \< 20x109/L. The cytopenia must be unexplained (such as by disease relapse) and unresponsive to hematopoietic growth factors and must last at least 4 weeks; 3. Secondary graft failure is defined as poor graft function associated with donor chimerism \< 5% after initial engraftment * Transplanted donor availability * Negative pregnancy test within seven (7) days of product infusion for women of childbearing potential. Exclusion Criteria: * Graft failure due to disease relapse or evidence of disease relapse or progression * Donor unavailable or unable to collect peripheral HPC by apheresis * Responsive to conventional measures (such as, hematopoietic growth factor) * Allergic reaction to murine proteins or iron dextran * Women of childbearing potential with positive serum HCG
About the study
The proposed trial is a single arm, non-randomized, single center pilot study utilizing CliniMACS CD34 Reagent System for patients following allogeneic hematopoietic stem cell transplant (HSCT) requiring treatment of graft dysfunction or failure.
What is being tested
- CD34+ Selected Donor Cell Boost (device)
- Blood Stem Cell Infusion (procedure)
Sponsor: NYU Langone Health · Participants: 21 · Started: Oct 31, 2024
Contact the study team
- Kiselle Mangalindan · Phone: 646-501-2973
- Kelsey Stocker · Phone: 646-501-4848
Official record on ClinicalTrials.gov — NCT06569082
Locations in the U.S.
| New York | NYU Langone Health, New York |
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.